MXPA03012041A - Sistema de administracion controlada de farmacos de retencion gastrica. - Google Patents

Sistema de administracion controlada de farmacos de retencion gastrica.

Info

Publication number
MXPA03012041A
MXPA03012041A MXPA03012041A MXPA03012041A MXPA03012041A MX PA03012041 A MXPA03012041 A MX PA03012041A MX PA03012041 A MXPA03012041 A MX PA03012041A MX PA03012041 A MXPA03012041 A MX PA03012041A MX PA03012041 A MXPA03012041 A MX PA03012041A
Authority
MX
Mexico
Prior art keywords
core
drug
delivery system
drug delivery
gastric retention
Prior art date
Application number
MXPA03012041A
Other languages
English (en)
Spanish (es)
Inventor
Bhalachandra Dharmadhika Nitin
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of MXPA03012041A publication Critical patent/MXPA03012041A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA03012041A 2001-07-04 2002-07-04 Sistema de administracion controlada de farmacos de retencion gastrica. MXPA03012041A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN612MU2001 2001-07-04
PCT/IN2002/000144 WO2003011255A1 (en) 2001-07-04 2002-07-04 Gastric retention controlled drug delivery system

Publications (1)

Publication Number Publication Date
MXPA03012041A true MXPA03012041A (es) 2004-03-26

Family

ID=32051199

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03012041A MXPA03012041A (es) 2001-07-04 2002-07-04 Sistema de administracion controlada de farmacos de retencion gastrica.

Country Status (17)

Country Link
US (2) US7776345B2 (https=)
EP (2) EP1411901B1 (https=)
JP (2) JP4994570B2 (https=)
KR (1) KR20040018394A (https=)
CN (1) CN1520286B (https=)
AT (1) ATE477795T1 (https=)
AU (1) AU2002355686B2 (https=)
BR (1) BR0211317A (https=)
CA (1) CA2452738C (https=)
DE (1) DE60237372D1 (https=)
ES (1) ES2398348T3 (https=)
HU (1) HUP0500795A3 (https=)
MX (1) MXPA03012041A (https=)
PL (1) PL370793A1 (https=)
RU (1) RU2325152C2 (https=)
WO (1) WO2003011255A1 (https=)
ZA (1) ZA200400799B (https=)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
ATE540678T1 (de) 2001-06-11 2012-01-15 Xenoport Inc Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
MXPA03012041A (es) * 2001-07-04 2004-03-26 Sun Pharmaceutical Ind Ltd Sistema de administracion controlada de farmacos de retencion gastrica.
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
CA2486794A1 (en) * 2002-06-04 2003-12-11 J. B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
AR040682A1 (es) 2002-07-25 2005-04-13 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
KR20110097942A (ko) 2003-08-20 2011-08-31 제노포트 인코포레이티드 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
US8246996B2 (en) * 2003-08-29 2012-08-21 Shionogi Inc. Antibiotic product, use and formulation thereof
US20050169991A1 (en) * 2003-12-12 2005-08-04 Penwest Pharmaceuticals Co. Sustained release torsemide dosage forms
WO2005060942A1 (en) * 2003-12-19 2005-07-07 Aurobindo Pharma Ltd Extended release pharmaceutical composition of metformin
TW200533391A (en) 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
WO2006014973A2 (en) 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
EA200700388A1 (ru) 2004-08-13 2007-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ её изготовления и её применение
FR2874325B1 (fr) * 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
DE102004042139B4 (de) * 2004-08-31 2009-06-10 Aristocon Verwaltungs- Gmbh Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
US20080020041A1 (en) * 2004-10-19 2008-01-24 Ayres James W Enteric Coated Compositions that Release Active Ingredient(s) in Gastric Fluid and Intestinal Fluid
WO2006050471A2 (en) 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
WO2006050472A2 (en) 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
CA2584338C (en) 2004-11-04 2013-08-06 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms
ES2540929T3 (es) * 2005-02-01 2015-07-14 Emisphere Technologies, Inc. Sistema de administración de retención gástrica y liberación controlada
EP1690540A1 (en) * 2005-02-15 2006-08-16 Neuro3D Composition comprising ocaperidone
US8431156B2 (en) * 2005-02-22 2013-04-30 Sun Pharma Advanced Research Company Ltd. Pharmaceutical composition
WO2006091657A1 (en) * 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
EP1745775B1 (en) * 2005-07-19 2008-05-28 Ethypharm Gastroretentive formulations and manufacturing process thereof.
WO2007048223A2 (en) * 2005-10-25 2007-05-03 Pharmascience Inc. A gastric retention drug delivery system
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
AU2007201808B8 (en) * 2006-04-26 2013-09-05 Sun Pharmaceutical Advanced Research Company Ltd A method for alleviating signs and symptoms of spasticity
US8703191B2 (en) * 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
UA96457C2 (ru) 2006-08-03 2011-11-10 Нитек Фарма Аг Лечение ревматоидного артрита глюкокортикоидами с отсроченным высвобождением
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
US20100016310A1 (en) * 2006-08-17 2010-01-21 Boehringer Ingelheim International Gmbh Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors
WO2008033572A1 (en) 2006-09-15 2008-03-20 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
KR20090057399A (ko) * 2006-09-26 2009-06-05 노파르티스 아게 Ｓ１ｐ 조정제를 포함하는 제약 조성물
EP2121107B1 (en) 2006-12-18 2012-10-31 Eatlittle Inc. Device for delivery of a substance
TR201910825T4 (tr) * 2006-12-22 2019-08-21 Ironwood Pharmaceuticals Inc Yemek borusu rahatsizliklarini tedavi̇ etmek i̇çi̇n yöntemler ve bi̇leşi̇mler
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
CN101011393B (zh) * 2007-02-16 2010-10-06 广州柏赛罗药业有限公司 厄贝沙坦胃内滞留型缓释药物组合物
DE102007026037A1 (de) 2007-06-04 2008-12-11 Lts Lohmann Therapie-Systeme Ag Gastroretentives System mit Alginat-Körper
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
HUP0700469A2 (en) * 2007-07-09 2009-04-28 Richter Gedeon Nyrt Floating pharmaceutical composition of sustained release containing metronidazol
EP2192892A2 (en) * 2007-07-27 2010-06-09 Depomed, Inc. Pulsatile gastric retentive dosage forms
EP2175840A2 (en) * 2007-08-14 2010-04-21 Dr. Reddy's Laboratories, Ltd. Pharmaceutical compositions comprising ropinirole
US20120003307A1 (en) * 2007-11-29 2012-01-05 Ranbaxy Laboratories Limited Levetiracetam controlled release composition
EP2065038A1 (en) * 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
WO2009097156A1 (en) * 2008-02-01 2009-08-06 Barr Laboratories, Inc. Pharmaceutical capsules comprising extended release dipyridamole pellets
US9457048B2 (en) 2008-02-05 2016-10-04 Wellosophy Corporation Absorbent ingestible agents and associated methods of manufacture and use
KR101601649B1 (ko) * 2008-04-18 2016-03-09 인텍 파마 리미티드 카르비도파／레보도파 위체류 약물 전달
ZA200903858B (en) * 2008-06-19 2013-10-30 Univ Of Witwatesrand Johannesburg Pharmaceutical dosage form
WO2009158625A2 (en) * 2008-06-26 2009-12-30 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing gastrointestinal disorders and gerd-related respiratory disorders
US8173637B2 (en) * 2008-07-24 2012-05-08 Handa Pharmaceuticals, Llc Stabilized atypical antipsychotic formulation
JP2012500221A (ja) * 2008-08-15 2012-01-05 ディポメド，インコーポレイティド Ｃｎｓ障害の処理及び予防のための胃保持性医薬組成物
JP2012510987A (ja) 2008-12-04 2012-05-17 インテック ファーマ リミテッド ザレプロン胃内滞留性薬剤送達システム
CA3014688A1 (en) 2008-12-19 2010-07-15 Supernus Pharmaceuticals, Inc. Use of molindone for the treatment of aggression, irritability, or impulsivity
AU2010207740B2 (en) * 2009-01-26 2016-06-16 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
EP2263657B1 (en) * 2009-05-20 2013-07-17 Ranbaxy Laboratories Limited Controlled release lamotrigine formulations
CN102438598B (zh) * 2009-05-27 2015-06-10 株式会社茶山医化 含有泡腾层的多层片
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
US20110104273A1 (en) * 2009-11-05 2011-05-05 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of phenylephrine
JP6045347B2 (ja) * 2010-02-03 2016-12-14 ファーマ ツー ビー リミテッド ラサギリンの持続放出性製剤およびその使用
CA2790164A1 (en) * 2010-02-17 2011-08-25 Sun Pharma Advanced Research Company Ltd. Method of treating a disease condition susceptible to baclofen therapy
WO2011123497A1 (en) * 2010-03-31 2011-10-06 Supernus Pharmaceuticals Inc. Stabilized formulations of cns compounds
KR101270751B1 (ko) * 2010-05-06 2013-06-07 (주)비씨월드제약 위 체류 및 방출 조절을 위한 조성물
US20130078290A1 (en) 2010-06-01 2013-03-28 Rubicon Research Private Limited Gastroretentive Dosage Forms Of GABA Analogs
HRP20151321T1 (hr) 2011-01-20 2016-01-29 Bionevia Pharmaceuticals Inc. Epalrestat ili njegov derivat u oblicima s prilagođenim otpuštanjem te postupci uporabe istih
AT511671A1 (de) * 2011-07-13 2013-01-15 Bischof Georg Dr Zusammensetzung zur erzeugung einer vorübergehenden okklusion des darms eines säugetiers
KR101438546B1 (ko) * 2011-08-26 2014-09-17 근화제약주식회사 프레가발린을 포함하는 서방성 제제
RU2489147C2 (ru) * 2011-08-31 2013-08-10 Людмила Петровна Лазурина Фармацевтическая антибактериальная композиция для местного применения на основе активных биометаллокомплексов
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
CN102440976A (zh) * 2011-12-21 2012-05-09 南京海陵中药制药工艺技术研究有限公司 依帕司他缓释片及其制备方法
NZ700474A (en) * 2012-04-18 2016-10-28 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
EP2950822B1 (en) * 2013-01-30 2019-04-24 Daewoong Co., Ltd. Pharmaceutical composition for protecting wounds, providing hemostasis, or preventing adhesion in the gastrointestinal tract
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
FR3014692B1 (fr) * 2013-12-18 2016-01-29 Ethypharm Sa Compositions pharmaceutiques orales a retention gastrique.
WO2016001843A1 (en) * 2014-06-30 2016-01-07 Sun Pharmaceutical Industries Limited Extended-release gastroretentive tablets of voglibose
US10172800B2 (en) 2015-02-20 2019-01-08 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form with enhanced pharmacokinetics
WO2016132218A1 (en) 2015-02-20 2016-08-25 Osmotica Kereskedelmi Es Szolgaltato Kft Method of administering r-baclofen in an extended release dosage form
US10987328B2 (en) 2015-02-20 2021-04-27 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10300032B2 (en) 2015-02-20 2019-05-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
RU2649834C1 (ru) * 2016-07-06 2018-04-04 Фармалидер С.А. Фармацевтическая композиция силденафила цитрата в форме суспензии для перорального применения
AU2017297718B2 (en) 2016-07-11 2023-06-08 Contera Pharma A/S Pulsatile drug delivery system for treating morning akinesia
FR3054218B1 (fr) * 2016-07-22 2020-03-06 Universite De Rouen Procede de dedoublement de sels de baclofene
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
EP3509592A4 (en) 2016-09-09 2020-07-22 Cutispharma, Inc. SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFEN
EP3345591A1 (en) * 2017-01-06 2018-07-11 Oystershell NV Oral dosage form for enhanced solubilization of a poorly soluble active agent and method of preparation
WO2018127594A1 (en) * 2017-01-06 2018-07-12 Oystershell Nv Oral dosage form for enhanced solubilization of a poorly soluble active agent and method of preparation
JP7521897B2 (ja) 2017-03-31 2024-07-24 アキュラ・ファーマシューティカルズ・インコーポレーテッド 医薬品有効成分の自己調節放出のための方法及び組成物
JP6823539B2 (ja) * 2017-05-26 2021-02-03 株式会社ファンケル 胃内滞留性錠剤
US10987311B2 (en) * 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
EP3648747B1 (en) * 2017-06-16 2022-09-07 Amneal Complex Products Research LLC Gastroretentive dosage forms for sustained drug delivery
US10588863B2 (en) * 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
EP3678648B1 (en) * 2017-09-08 2023-07-26 Insignis Therapeutics, Inc. Methods of using dipivefrin
CN109985016B (zh) * 2017-12-29 2021-07-27 江苏恒瑞医药股份有限公司 一种非布司他的控释组合物及其制备方法
ES2861153T3 (es) * 2018-06-18 2021-10-05 Composiciones de liberación prolongada que comprenden piridostigmina
CN112469400A (zh) * 2018-06-19 2021-03-09 新加坡国立大学 对于各种适应症的生物利用度更佳的5-羟色氨酸(5-htp)制剂
JP7034343B2 (ja) 2018-06-27 2022-03-11 アムニール コンプレックス プロダクツ リサーチ エルエルシー 自己調節性の浸透性胃保持性薬物送達システム
JP7044649B2 (ja) * 2018-06-28 2022-03-30 株式会社ファンケル 胃内浮遊錠剤
WO2020011938A1 (en) 2018-07-11 2020-01-16 Medizinische Universität Wien Glucocorticoids for the topical treatment of autoimmune gastritis
WO2020131780A1 (en) * 2018-12-18 2020-06-25 Ddp Specialty Electronics Materials Us, Inc. A sustained release composition comprising a methylcellulose
EP3968980A1 (en) 2019-05-14 2022-03-23 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
RU2751163C9 (ru) * 2020-04-06 2021-10-20 Общество С Ограниченной Ответственностью "Ниармедик Плюс" Фармацевтическая композиция на основе макозинона для лечения туберкулеза, включая его формы с множественной и широкой лекарственной устойчивостью.
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions
AU2022395186A1 (en) * 2021-11-25 2024-05-30 Orexa B.V. Gastro-retentive oral dosage unit containing a local anaesthetic
CN114796142A (zh) * 2022-04-08 2022-07-29 黄山学院 萘普生胃漂浮片及其制备方法
CN115444831B (zh) * 2022-10-25 2023-08-22 南京康川济医药科技有限公司 一种依帕司他胃漂浮片及其制备方法
CN115721621A (zh) * 2022-12-16 2023-03-03 杭州剂泰医药科技有限责任公司 一种依帕司他缓释制剂
CN117137877A (zh) * 2023-10-09 2023-12-01 重庆士立德医药科技有限公司 一种巴氯芬缓释片及其制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4101650A (en) * 1977-04-06 1978-07-18 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Pepstatin floating minicapsules
SE8404467D0 (sv) * 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
DE3681348D1 (de) * 1985-06-11 1991-10-17 Teijin Ltd Oral-arzneizubereitung mit retardwirkung.
JPS62195323A (ja) * 1986-02-24 1987-08-28 Eisai Co Ltd 胃内滞留型粒子
US4772473A (en) * 1986-06-16 1988-09-20 Norwich Eaton Pharmaceuticals, Inc. Nitrofurantoin dosage form
JPH0798742B2 (ja) 1986-07-03 1995-10-25 ゼリア新薬工業株式会社 徐放性製剤組成物
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
IL87710A (en) * 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
US4892739A (en) * 1988-04-25 1990-01-09 Ciba-Geigy Corporation Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having a improved core membrane adhesion properties
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
PH26730A (en) * 1988-12-30 1992-09-28 Ciba Geigy Ag Coated adhesive tablets
HU213407B (en) * 1993-12-09 1997-06-30 Egyt Gyogyszervegyeszeti Gyar Process for producing tablet with diffusive-osmotic release
DE4406424A1 (de) 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
WO1997020551A1 (en) * 1995-12-05 1997-06-12 Adcock Ingram Limited Pharmaceutical composition comprising a skeletal muscle relaxant, a non-steroidal antiinflammatory agent and an analgesic
US6271278B1 (en) 1997-05-13 2001-08-07 Purdue Research Foundation Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties
CA2290624C (en) * 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
IN186245B (https=) * 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
EP1063973B1 (en) 1998-03-19 2016-11-16 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
ATE245414T1 (de) * 1998-09-14 2003-08-15 Ranbaxy Lab Ltd Oral verabreichtes system zur zeitlich und räumlich gesteuerten arzneistoffabgabe
FR2784583B1 (fr) 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
WO2000035419A2 (en) * 1998-12-17 2000-06-22 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
AU2199500A (en) * 1998-12-23 2000-07-31 Alza Corporation Gastric retention dosage form having multiple layers
AU6381000A (en) 1999-07-29 2001-02-19 Interneuron Pharmaceuticals, Inc. Methods and compositions for alleviating stuttering
WO2001010405A1 (en) 1999-08-04 2001-02-15 Ranbaxy Laboratories Limited Hydrodynamically balanced oral drug delivery system
FR2797185B1 (fr) 1999-08-06 2001-10-26 Galenix Dev Composition pharmaceutique flottante comprenant une phase active et une phase non active
EP1095650A1 (en) * 1999-10-29 2001-05-02 Universiteit Leiden Double phase time-controlled release system
MXPA03012041A (es) * 2001-07-04 2004-03-26 Sun Pharmaceutical Ind Ltd Sistema de administracion controlada de farmacos de retencion gastrica.
KR20110097942A (ko) * 2003-08-20 2011-08-31 제노포트 인코포레이티드 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
AU2007201808B8 (en) * 2006-04-26 2013-09-05 Sun Pharmaceutical Advanced Research Company Ltd A method for alleviating signs and symptoms of spasticity

Also Published As

Publication number Publication date
EP1411901B1 (en) 2010-08-18
CA2452738C (en) 2011-06-14
US7776345B2 (en) 2010-08-17
ES2398348T3 (es) 2013-03-15
KR20040018394A (ko) 2004-03-03
CN1520286B (zh) 2010-12-01
JP2010090161A (ja) 2010-04-22
ATE477795T1 (de) 2010-09-15
CA2452738A1 (en) 2003-02-13
EP2238975B1 (en) 2012-12-05
US8012496B2 (en) 2011-09-06
JP4994570B2 (ja) 2012-08-08
US20040180088A1 (en) 2004-09-16
ZA200400799B (en) 2005-07-27
PL370793A1 (en) 2005-05-30
WO2003011255A1 (en) 2003-02-13
AU2002355686B2 (en) 2007-11-29
RU2003138075A (ru) 2005-06-10
BR0211317A (pt) 2004-12-14
EP2238975A1 (en) 2010-10-13
RU2325152C2 (ru) 2008-05-27
HUP0500795A2 (en) 2007-02-28
DE60237372D1 (de) 2010-09-30
EP1411901A1 (en) 2004-04-28
HUP0500795A3 (en) 2008-04-28
US20100305208A1 (en) 2010-12-02
JP2004538301A (ja) 2004-12-24
CN1520286A (zh) 2004-08-11

Similar Documents

Publication Publication Date Title
MXPA03012041A (es) Sistema de administracion controlada de farmacos de retencion gastrica.
DE69917866D1 (de) Bupropionhydrochlorid enthaltende Tabletten mit gesteuerter Wirkstoffabgabe
MY148867A (en) Gastric retention drug delivery system
AU5680100A (en) Controlled release and taste masking oral pharmaceutical compositions
WO2003028660A3 (en) Drug delivery devices and methods
ATE269709T1 (de) Tablette mit verzögerter freigabe enthaltend einen blutzuckersenkenden wirkstoff und einen antihyperglyzemischen wirkstoff
BR0103033A (pt) Partìculas farmacêuticas de sabor mascarado
WO2004000379A8 (en) Stent coatings with sustained drug release rate
MY130332A (en) Pharmaceutical formulation comprising iota-carrageenan and at least one neutral gelling polymer
AP2001002237A0 (en) Hydrogel-driven drug dosage form.
WO2007008752A3 (en) Sustained release pharmaceutical compositions for highly water soluble drugs
WO2002072033A3 (en) Chronotherapeutic dosage forms containing glucocorticosteroid
YU35302A (sh) Dozirani oblik leka sa inicijalnim hidrogelom
WO2004047768A3 (en) Buoyant polymer particles delivering therapeutic agents
WO2005097064A3 (en) Taste-masked drugs in rupturing multiparticulates
IL154731A0 (en) Ion-strength independent sustained release pharmaceutical formulation
WO2006030402A3 (en) Dual compartment osmotic delivery device
CA2417887A1 (en) Particulate composition of eletriptan
WO2004062552A3 (en) Pharmaceutical composition containing a nsaid and a benzimidazole derivative
SI0976395T1 (sl) Tableta s podaljsanim sproscanjem zdravilne ucinkovine v zelodcu
AP2001002084A0 (en) Orally administered controlled delivery system for once daily adminstration of ciprofloxacin
WO2003096968A3 (en) Oral osmotic controlled drug delivery system
WO2007016350A3 (en) Modified release tablet formulations with enhanced mechanical properties
EP1680098A4 (en) DELAYED RELEASE OF POSITIVELY-LOADED PHARMACOLOGICALLY EFFECTIVE MOLECULES FROM A POLYMER-CONTAINING MATRIX WITH POLARIZED OXYGENATOMES
MXPA06007511A (es) Revestimientos de granulos de farmaco que imparten resistencia a la embarradura durante la compresion mecanica.

Legal Events

Date Code Title Description
FG Grant or registration